Inmaculada Buendía Jiménez

Dr. Inmaculada Buendía Jiménez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Trials
Verified
Journal Article
Open access
PDF file
IJInmaculada Buendía Jiménez
Inmaculada Buendía Jiménez
MMMaría Matas-Ros
María Matas-Ros
TGTeresa Garriga-Baraut
Teresa Garriga-Baraut
ARAlbert Roger-Reig
Albert Roger-Reig
ATAna Tabar-Purroy
Ana Tabar-Purroy
MGMiguel Tortajada Girbés
Miguel Tortajada Girbés
There is an important heterogeneity of the clinical research done to date for allergen immunotherapy (AIT). We plan to assess the safety and efficacy of a house dust mite (HDM) polymerized allergen extract mixture for allergic rhinoconjunctivitis (AR) according to both the EMA and European Academy of Allergy and Clinical Immunology (EAACI) guidelines for the clinical development of products for the treatment of AR. We will perform a double-blind, placebo-controlled, randomized parallel group phase III clinical trial to assess the clinical efficacy and safety of a polymerized Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extract mixture (Beltavac®) to treat perennial AR in children and adults. Patients with moderate or severe rhinitis symptoms, either associated or not with asthma and confirmed HDM sensitization and without relevant concomitant conditions that may interfere with the planned evaluations test are eligible. Patients will be randomized in a 1:1 ratio to either the active AIT or placebo. The experimental group will receive 12 monthly AIT doses via subcutaneous route with a potency of 2 RC/ml per allergen. The expected sample size is 250 patients from 16 sites in Spain. The main efficacy outcome is the Combined Symptom and Medication Score (CSMS) for rhinitis. It will be patients’ self-assessed and collected through a phone App developed ad hoc for the study to improve the patient adherence and the quality of data. Main secondary outcomes include expanded CSMS for rhinoconjunctivitis symptoms, control of rhinitis, specific IgE and IgG4 values, quality of life, and the number of adverse reactions. Health-related direct and indirect costs will be also evaluated. Finally, several exploratory parameters will be used to assess the severity of asthma. This phase III clinical trial will be of interest to contribute to the scientific evidence about the efficacy and safety of AIT with allergoids. Our working hypothesis is that the investigational product in patients with AR associated or not with asthma is superior to placebo in providing a clinically significant improvement according to the standards defined by the EAACI. This trial will also supply valuable information about patients reported outcomes using health technology for rhinoconjunctivitis and asthma assessment. EudraCT 2018–003427-11. Date on which this record was first entered in the: 2021–06-14.

15 March 2021 in Allergo Journal International
Verified
Journal Article
Closed access
PDF file
EPElena Rodríguez Plata
Elena Rodríguez Plata
GSGuacimara L. Hernández Santana
Guacimara L. Hernández Santana
EMEstefanía Cubas Mesa
Estefanía Cubas Mesa
KVKevin Coello Valeriano
Kevin Coello Valeriano
MRMaría Matas Ros
María Matas Ros
IJInmaculada Buendía Jiménez
Inmaculada Buendía Jiménez

Verified
Journal Article
Open access
PDF file
IJInmaculada Buendía Jiménez
Inmaculada Buendía Jiménez
MRMaria Matas Ros
Maria Matas Ros
TGTeresa Garriga-Baraut
Teresa Garriga-Baraut
MCMaría Araceli Caballero-Rabasco
María Araceli Caballero-Rabasco
APAmalui Vásquez Pérez
Amalui Vásquez Pérez
ACAlfons Malet i Casajuana
Alfons Malet i Casajuana
Background/Objectives: Allergen immunotherapy is the sole therapeutic option capable of modifying the natural course of allergic rhinitis and preventing the development of asthma. Results from paediatric patients are scarce. To evaluate the effectiveness and safety of a glutaraldehyde-modified extract of mites (Beltavac®) administered for one year under clinical routine conditions in children between 3 and 11 years old. Methods: This was a multicentre, prospective, 13-month cohort study. Among 97 children diagnosed with immunoglobulin E-mediated house dust mite allergic rhinoconjunctivitis, 87 initiated the subcutaneous immunotherapy. The main outcomes included the Combined Symptoms and Medication Score (CSMS), assessed for 1 month at baseline and after 1, 6, and 12 months, and the number of adverse reactions according to the WAO adverse reaction grading system. The levels of serum-specific immunoglobulins were also assessed. Results: CSMS improved scores throughout therapy (adjusted mean change and 95% confidence interval: 0.55, 0.26–0.84 points; p < 0.001). Improvements occurred in both children with (n = 68) and without asthma (n = 19), as well as in children aged ≥6 years (n = 76) and <6 years (n = 11), although statistical significance was not reached in the smallest subgroups. Eight children (9.2%) developed a total of 15 adverse reactions. Most occurred after the initial dose (five out of eight children), and were local (six out of eight) and minor (five out of eight). Over 90% of patients completed the full regimen. Conclusions: This study supports the effectiveness and safety of allergen immunotherapy administered according to a rush schedule for one year for paediatric allergic rhinitis.